A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer. The two-drug combination was effective against advanced cancers with a range of mutations to the .
/PRNewswire/ Faron Pharmaceuticals Ltd. ("Faron") Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not.
/PRNewswire/ Faron Pharmaceuticals Ltd. ("Faron") Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not.